Clinicopathologic Significance of the Expression of Mutated P53 Protein and the Proliferative Activity of Cancer Cells in Patients with Esophageal Squamous Cell Carcinoma

Ikeguchi, Masahide; Saito, Hiroaki; Katano, Kuniyuki; Tsujitani, Shunichi; Maeta, Michio; Kaibara, Nobuaki

doi:10.1016/s1072-7515(01)00947-4

Cited by 17 publications

(13 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…37) In these cases, P53 can be detected immunohistochemically, and whether detected P53 is functional or not is undistinguishable. These may be the reasons why P53 accumulation has been reported to show no correlation with the prognosis of ESCC patients, [38][39][40][41][42][43][44][45] and why in our study, multivariate analysis of clinicopathological and immunohistochemical factors for lymph node metastasis did not show a significant relationship between P53 accumulation and lymph node metastasis, although P53 accumulation showed significant relationship with lymph node metastasis by univariate and multivariate analysis focusing on immunohistochemical factors.…”

Section: )contrasting

confidence: 60%

Evaluation of an Indicator for Lymph Node Metastasis of Esophageal Squamous Cell Carcinoma Invading the Submucosal Layer

Nakajima¹,

Nagai²,

Miyaké³

et al. 2002

Japanese Journal of Cancer Research

View full text Add to dashboard Cite

Lymph node metastasis is a major prognostic factor for esophageal squamous cell carcinoma (ESCC). In recent years, endoscopic mucosal resection (EMR) has been developed with excellent results for the treatment of the superficial ESCC. To make the EMR treatment successful, it is important to establish a good indicator to identify ESCC patients at a high risk of lymph node metastasis. In this study, we examined clinicopathological and immunohistochemical factors to investigate the factors involved in lymph node metastasis of ESCC invading to the submucosal layer (sm‐ESCC). Surgical specimens from 84 sm‐ESCC patients were examined. Among 84 sm‐ESCC patients, 33 (39.3%) had lymph node metastases. Clinicopathologically, tumor depth, lymphatic invasion and blood vessel invasion showed significant correlations with lymph node metastasis by univariate analysis. Tumor depth and lymphatic invasion showed significant correlations by multivariate analysis of these factors. Immunohistochemically, P53 accumulation was observed in 45 cases (53.6%), cyclin D1 overexpression in 25 (29.8%), and pRB in 65 (77.4%). P53 accumulation, cyclin D1 overexpression and MIB‐1 Labeling Index were significantly associated with lymph node metastasis by univariate analysis, and P53 accumulation showed a significant correlation with lymph node metastasis by multivariate analysis. Among tumor depth, lymphatic invasion and P53 accumulation, tumor depth and lymphatic invasion were significantly correlated with lymph node metastasis (P=0.0023 and P=0.0092, respectively) by multivariate analysis. These data suggest that tumor depth and lymphatic invasion can be considered as good indicators for lymph node metastasis among patients with sm‐ESCC. In addition, P53 accumulation could be helpful to identify the patients who need additional treatment after EMR.

show abstract

Section: )contrasting

confidence: 60%

Evaluation of an Indicator for Lymph Node Metastasis of Esophageal Squamous Cell Carcinoma Invading the Submucosal Layer

Nakajima¹,

Nagai²,

Miyaké³

et al. 2002

Japanese Journal of Cancer Research

View full text Add to dashboard Cite

show abstract

“…p53 protein expression was not correlated with the progression (invasion) of tumor. This indicates that p53 gene mutations do not change at a statistically significant rate in these stages, and that mutations occur at earlier stages (I), and probably increase in more advanced stages (IV) of the disease 15 . Moreover, p53 protein expression was not a prognostic factor either in univariate or multivariate analysis, and was not correlated with the other clinicopathologic characteristics.…”

Section: Discussionmentioning

confidence: 89%

“…Most studies that included a predominant number of patients with SCC of the esophagus report that p53 protein expression is not associated with a worse long-term survival. 15,[17][18][19][20][21] On the other hand, some studies report that p53 protein expression is associated with a poor prognosis. [22][23][24] Such discrepancy is explained by the fact that several studies include patients with different histologic types of cancer (adenocarcinoma and epidermoid carcinoma), tumors at different stages, or different types of resection (palliative or curative).…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of p53 protein expression and vascular endothelial growth factor expression in resected squamous cell carcinoma of the esophagus

Rosa

Schirmer

Gurski

et al. 2003

Diseases of the Esophagus

View full text Add to dashboard Cite

The most common genetic alterations found in a wide variety of cancers are p53 tumor suppressor gene mutations. p53 appears to be a nuclear transcription factor that plays a role in the control of cell proliferation, apoptosis, and the maintenance of genetic stability. Angiogenesis is a critical process in solid tumor growth and metastasis. Vascular endothelial growth factor (VEGF), a recently identified growth factor with significant angiogenic properties, may be a major tumor angiogenesis regulator. Few studies have investigated the association between p53 and VEGF expressions and prognosis in esophageal carcinoma. Forty-seven specimens resected from patients with stage II and III squamous cell carcinoma (SCC) of the esophagus were studied using immunohistochemical staining. VEGF and p53 expressions were observed in 40% and 53% of the tumors, respectively. The p53 and VEGF staining statuses were coincident in only 21% of the tumors, and no significant correlation was found between p53 and VEGF statuses. No clinicopathologic factors were significantly correlated with p53 or VEGF expression. No significant association between p53 and VEGF expressions and poor prognosis was found. In conclusion, p53 and VEGF were not correlated with prognosis in patients with stage II and III SCC of the esophagus.

show abstract

“…The same report described extensive mutation when exons 5-8 of those tumors with p53 genes that did not respond to the treatment were observed, suggesting that the expression of wild-type p53 protein in a tumor can be a marker for chemoradiosensitivity. On the basis of this report, Ikeguchi et al (18) examined the expression of mutant p53 protein and the duration of cancer recurrence on resected specimens of a progressive esophageal cancer case that was categorized as non-curative resection due to residual cancer cells, and reported the potential of the mutant p53 protein expression as a marker for chemoradiosensitivity (19). Unfortunately, the usefulness of the expression of mutant p53 protein as a marker for sensitivity to PCRT has not yet been established.…”

Section: Discussionmentioning

confidence: 99%

Usefulness of serum protein profiling for prediction of preoperative chemoradiosensitivity of esophageal cancer

Ota

Takagi²,

Osaka³

et al. 2007

Oncol Rep

View full text Add to dashboard Cite

Abstract. We examined whether serum protein profiling is a reliable index for prediction of therapeutic efficacy of preoperative chemoradiotherapy (PCRT) in advanced esophageal cancer compared with evaluation of the efficacy of conventional clinical examination. We entered 42 patients who received PCRT and surgery between 1998 and 2002 into this study. Serum protein profiling was performed using the preoperative serum of the patient to select the marker set that enabled the efficacy of PCRT to be evaluated accurately. The efficacy of PCRT was predicted with the marker set, and the sensitivity, specificity and accuracy of the method were calculated based on evaluation of the efficacy by pathological examination. Similarly, therapeutic efficacy was also predicted based on evaluation of the efficacy of conventional clinical examination, and the results were compared with those of prediction by serum protein profiling. The correlation between each predictive examination and outcome was evaluated. The sensitivity, specificity and accuracy of prediction of therapeutic efficacy of PCRT by serum protein profiling were 90.9, 100 and 93.3%, respectively. In clinical examination, prediction of the efficacy of PCRT by three methods was as follows: by esophagography, sensitivity 76.0%, specificity 17.6%, accuracy 52.4%; by endoscopy, sensitivity 80.0%, specificity 11.8%, accuracy 52.4%; by computed tomography, sensitivity 60.0%, specificity 47.1%, accuracy 54.8%, respectively. These results demonstrated the superiority of serum protein profiling in predicting the therapeutic efficacy of PCRT compared with conventional clinical examination. Moreover, serum protein profiling was the only significant prognostic factor as regards the correlation with outcome by multivariate analysis. IntroductionEsophageal cancer generally has a poor prognosis and cannot be cured by surgery alone because it readily develops lymph node metastasis or invades into the trachea, bronchi or large vessels, especially if advanced. Since esophageal cancer is sensitive to chemotherapy and radiotherapy, various approaches to multidisciplinary treatment in which chemoradiotherapy is combined with surgical treatment have been made. Among them, preoperative chemoradiotherapy (PCRT), which came into use in the 1980s in Europe and North America, is reported to enhance the treatment results of advanced esophageal cancer by improving resection rates evaluating local control or by inhibiting post-operative recurrence by controlling minute metastatic lesions (1-3). However, several studies have revealed that PCRT does not affect all patients with esophageal cancer but improves the survival rates only when it is pathologically effective (4,5). In ineffective cases, PCRT is actually disadvantageous due to its side effects. It is therefore important to properly predict the therapeutic efficacy of PCRT and to use PCRT only for those cases in which effect can be anticipated. In order to discover a new diagnostic that can accurately predict the efficacy of PCRT, we perfo...

show abstract

Clinicopathologic Significance of the Expression of Mutated P53 Protein and the Proliferative Activity of Cancer Cells in Patients with Esophageal Squamous Cell Carcinoma

Cited by 17 publications

References 21 publications

Evaluation of an Indicator for Lymph Node Metastasis of Esophageal Squamous Cell Carcinoma Invading the Submucosal Layer

Evaluation of an Indicator for Lymph Node Metastasis of Esophageal Squamous Cell Carcinoma Invading the Submucosal Layer

Prognostic value of p53 protein expression and vascular endothelial growth factor expression in resected squamous cell carcinoma of the esophagus

Usefulness of serum protein profiling for prediction of preoperative chemoradiosensitivity of esophageal cancer

Contact Info

Product

Resources

About